Award recordCONTRACT

NOVARTIS PHARMACEUTICALS CORPORATION

PIID 36C24920N0173· VHA· 249-NETWORK CONTRACT OFFICE 9 (36C249)· 6505 · DRUGS AND BIOLOGICALS· FY2020· $283,568 net obligations· UEI NG61ZA8TADW3· NJ

Description

DRUG TISAGENLECLEUCEL TRADE NAME: KYMRIAH DEOBLIGATE $1,336.08 TO CLOSE OUT THE TASK ORDER.

Base award description: DRUG TISAGENLECLEUCEL TRADE NAME: KYMRIAH

First action · last action
2019-10-18 · 2020-03-04
Transactions
2
First transaction's obligation
$284,904
Base + all options value (sum of deltas)
$283,568
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D30268
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$284,904$0Base award · 2019-10-18 · this action $284,904 · running total $284,904Modification P00001 · 2020-03-04 · this action -$1,336 · running total $283,568
  • Base2019-10-18+$284,904= $284,904
  • Mod P000012020-03-04-$1,336= $283,568
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2019-10-18+$284,904$284,904DRUG TISAGENLECLEUCEL TRADE NAME: KYMRIAH
Mod P00001· FUNDING ONLY ACTION2020-03-04−$1,336$283,568DRUG TISAGENLECLEUCEL TRADE NAME: KYMRIAH DEOBLIGATE $1,336.08 TO CLOSE OUT THE TASK ORDER.

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI NG61ZA8TADW3)

AwardOffice · PSC / listingNet obligationsFY
36C25526N0394255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS$891,651FY2026
36C26226F0314262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS$823,062FY2026
36C24526N0724245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$34,874FY2026
36C24526N0622245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$34,874FY2026
36C25026N0416250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS$617,297FY2026
36C24526N0566245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$34,874FY2026

Other recipients under 6505 from 249-NETWORK CONTRACT OFFICE 9 (36C249) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C24926N0676AMICUS THERAPEUTICS US, LLC249-NETWORK CONTRACT OFFICE 9 (36C249)$68,519FY2026
36C24926N0651BRISTOL-MYERS SQUIBB COMPANY249-NETWORK CONTRACT OFFICE 9 (36C249)$378,650FY2026
36C24926N0658BRISTOL-MYERS SQUIBB COMPANY249-NETWORK CONTRACT OFFICE 9 (36C249)$364,139FY2026
36C24926N0590BRISTOL-MYERS SQUIBB COMPANY249-NETWORK CONTRACT OFFICE 9 (36C249)$364,139FY2026
36C24926N0589BRISTOL-MYERS SQUIBB COMPANY249-NETWORK CONTRACT OFFICE 9 (36C249)$364,139FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24920N0173_3600_V797D30268_3600 · retrieved 2026-09-26.